Another week, another new initiative for IBM Watson Health.
Wednesday, IBM announced the formation of a Watson Health medical imaging collaborative, seeking to make “cognitive imaging” a routine part of medical practice in oncology, neurology, diabetes care, eye care, cardiovascular disease and other image-heavy specialties. “Imaging is one of the things that spans across many different areas,” said Anne Le Grand, IBM Watson Health’s vice president of imaging.
Between June 2015 and June 2016, we’ve created more spaces and places for people to engage with the Science Center; honed and expanded our programs to support innovation and entrepreneurship; and enhanced the way we talk about our role in Greater Philadelphia’s innovation ecosystem.
Join us for a thrilling evening of start-up pitches from multiple sectors in healthcare including: Services, Health IT, Biotechnology, Medical Devices and Diagnostics. Applications are still being accepted, so if you not afraid of getting nipped by one of our judges, send your information to jhausfeld@sopenet.org.
The University System of Maryland is hoping a new $25 million venture capital fund it established will help spin off more commercial businesses — with the system reaping the benefits in the long run.
Qiagen and CosmosID have joined the Metagenomics and Metadesign of Subways and Urban Biomes (MetaSUB) consortium, an international five-year effort led by Weill Cornell Medicine, to map the genomes and epigenomes of microbial communities in 54 cities in 32 countries.
The first proposed test of CRISPR gene-editing technology in human beings is being funded by Internet billionaire Sean Parker, MIT Technology Review has learned.
The novel cancer treatment, initially disclosed last week, is being reviewed Tuesday by a federal advisory panel in Washington, D.C., and could become the first clinical trial involving CRISPR, the red-hot gene modification technology.
Innovation Village, an effort to spur economic development in West Baltimore, is partnering with Howard County’s Conscious Venture Lab to help develop fledgling companies and entrepreneurs.
When David R. Tabatadze’s small biotechnology venture ran out of money in 2013, he almost gave up on it.
He went to pharmaceutical companies and “angel” investors, those individuals willing to put modest amounts of money into new businesses. None were interested in funding his research into potential genetic medicines.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55, the company’s large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
Imagine the workplace during flu season. Some people get sick and display clear symptoms—a warning sign to coworkers to avoid contact and for that individual to stay home. Others are infected, but never or only belatedly exhibit the tell-tale signs of sickness, meaning they can infect coworkers without knowing it. If healthcare professionals had the ability to test in advance whether a person is likely to spread a disease following infection, they could recommend specific measures to treat the person or limit exposure and perhaps keep an outbreak from growing into an epidemic or pandemic.
